[HTML][HTML] Translational advances in pancreatic ductal adenocarcinoma therapy
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is most frequently
detected at advanced stages, limiting treatment options to systemic chemotherapy with …
detected at advanced stages, limiting treatment options to systemic chemotherapy with …
Cell death in pancreatic cancer: from pathogenesis to therapy
Pancreatic cancer is a devastating gastrointestinal cancer characterized by late diagnosis,
limited treatment success and dismal prognosis. Exocrine tumours account for 95% of …
limited treatment success and dismal prognosis. Exocrine tumours account for 95% of …
[HTML][HTML] Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
Y Qian, Y Gong, Z Fan, G Luo, Q Huang… - Journal of hematology & …, 2020 - Springer
Pancreatic ductal adenocarcinoma (PDAC) is a malignancy characterized by a poor
prognosis and high mortality rate. Genetic mutations and altered molecular pathways serve …
prognosis and high mortality rate. Genetic mutations and altered molecular pathways serve …
[HTML][HTML] Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches
M Orth, P Metzger, S Gerum, J Mayerle, G Schneider… - Radiation …, 2019 - Springer
Pancreatic ductal adenocarcinoma (PDAC) is a highly devastating disease with poor
prognosis and rising incidence. Late detection and a particularly aggressive biology are the …
prognosis and rising incidence. Late detection and a particularly aggressive biology are the …
Protective autophagy elicited by RAF→ MEK→ ERK inhibition suggests a treatment strategy for RAS-driven cancers
CG Kinsey, SA Camolotto, AM Boespflug, KP Guillen… - Nature medicine, 2019 - nature.com
Pancreatic ductal adenocarcinoma (PDA) was responsible for~ 44,000 deaths in the United
States in 2018 and is the epitome of a recalcitrant cancer driven by a pharmacologically …
States in 2018 and is the epitome of a recalcitrant cancer driven by a pharmacologically …
KRAS: the critical driver and therapeutic target for pancreatic cancer
RAS genes (HRAS, KRAS, and NRAS) comprise the most frequently mutated oncogene
family in human cancer. With the highest RAS mutation frequencies seen with the top three …
family in human cancer. With the highest RAS mutation frequencies seen with the top three …
Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
DA Ruess, GJ Heynen, KJ Ciecielski, J Ai… - Nature medicine, 2018 - nature.com
The ubiquitously expressed non-receptor protein tyrosine phosphatase SHP2, encoded by
PTPN11, is involved in signal transduction downstream of multiple growth factor, cytokine …
PTPN11, is involved in signal transduction downstream of multiple growth factor, cytokine …
[HTML][HTML] Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
M Holderfield, BJ Lee, J Jiang, A Tomlinson… - Nature, 2024 - nature.com
Abstract RAS oncogenes (collectively NRAS, HRAS and especially KRAS) are among the
most frequently mutated genes in cancer, with common driver mutations occurring at codons …
most frequently mutated genes in cancer, with common driver mutations occurring at codons …
Therapeutic strategies to target RAS-mutant cancers
MB Ryan, RB Corcoran - Nature reviews Clinical oncology, 2018 - nature.com
RAS genes are the most commonly mutated oncogenes in cancer, but effective therapeutic
strategies to target RAS-mutant cancers have proved elusive. A key aspect of this challenge …
strategies to target RAS-mutant cancers have proved elusive. A key aspect of this challenge …
[HTML][HTML] Pancreatic adenocarcinoma
DP Ryan, TS Hong, N Bardeesy - New England Journal of …, 2014 - Mass Medical Soc
Pancreatic Adenocarcinoma | NEJM Skip to main content NEJM Group Follow Us Facebook
Twitter Instagram YouTube LinkedIn Prepare to become a physician, build your knowledge …
Twitter Instagram YouTube LinkedIn Prepare to become a physician, build your knowledge …